The research proposed in this renewal application is based on both the enhanced understanding of IFNgamma receptor signaling we have gained from studies previously supported by this grant and from our novel observation demonstrating that IFNgamma plays a critical role in promoting immune responses to primary and transplantable tumors and that the tumor itself is a critical target of IFNgamma's actions. Our recent work has revealed that a significant percentage of human and murine tumors develop an adaptive insensitivity to IFNgamma. Preliminary data reveals that this insensitivity may, at least in part, be due to inactivating mutations in the genes encoding the IFNgamma Receptor signaling proteins. We have thus formed the testable hypothesis that somatic mutations in genes encoding IFNgamma receptor signaling components may provide a developing tumor with a mechanism to escape immunologic detection and destruction. The overall goals of the proposed research are thus to define the mechanisms underlying development of IFNgamma insensitivity not only in established tumor cell lines but also in primary human and murine tumors, determine the functional outcome of this process and explore whether defining the IFNgamma sensitivity of primary human tumors at biopsy can serve as a prognostic indicator of a tumor patient's clinical course. This proposal thus represents a balanced combination of basic and translational research. To achieve our research goals we intend to pursue the following three specific aims.
Specific Aim 1 seeks to elucidate the mechanisms leading to the development of IFNgamma insensitivity in human tumor cells lines and define the types of human tumor lines that display the insensitive phenotype.
In Specific Aim 2 we will characterize the molecular mechanisms leading to IFNgamma-insensitivity in primary murine tumors and define the biological consequences of the insensitivity.
In Specific Aim 3 we plan to determine whether IFNgamma insensitivity can be detected in fresh primary and metastatic human tumors and characterize the molecular mechanisms involved. These studies should thus define the molecular and genetic bases and clinical relevance of a frequent but previously unappreciated mechanism that tumors use to escape immunologic destruction that is of significant potential clinical relevance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043059-18
Application #
6732095
Study Section
Special Emphasis Panel (ZRG1-ALY (03))
Program Officer
Mccarthy, Susan A
Project Start
1986-02-01
Project End
2008-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
18
Fiscal Year
2004
Total Cost
$407,037
Indirect Cost
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Noguchi, Takuro; Ward, Jeffrey P; Gubin, Matthew M et al. (2017) Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5:106-117
Ward, Jeffrey P; Gubin, Matthew M; Schreiber, Robert D (2016) The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Adv Immunol 130:25-74
Griffith, Obi L; Chan, Szeman Ruby; Griffith, Malachi et al. (2016) Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Rep 17:249-260
Gubin, Matthew M; Artyomov, Maxim N; Mardis, Elaine R et al. (2015) Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125:3413-21
Sheehan, Kathleen C F; Lazear, Helen M; Diamond, Michael S et al. (2015) Selective Blockade of Interferon-? and -? Reveals Their Non-Redundant Functions in a Mouse Model of West Nile Virus Infection. PLoS One 10:e0128636
Chang, Chih-Hao; Qiu, Jing; O'Sullivan, David et al. (2015) Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162:1229-41
Mittal, Deepak; Gubin, Matthew M; Schreiber, Robert D et al. (2014) New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27:16-25
Gubin, Matthew M; Zhang, Xiuli; Schuster, Heiko et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577-81
Lee, Sang Hun; Carrero, Javier A; Uppaluri, Ravindra et al. (2013) Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-? receptor subunit 1 (IFNGR1). J Immunol 191:4223-34
Pan, Hua; Myerson, Jacob W; Hu, Lingzhi et al. (2013) Programmable nanoparticle functionalization for in vivo targeting. FASEB J 27:255-64

Showing the most recent 10 out of 76 publications